ArticleClinical and experimental dermatology2022
Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine.
Article in Clinical and experimental dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Pooled it
- Linear IgA bullous dermatosis in a child after the second dose of inactivated COVID-19 vaccine.Postepy dermatologii i alergologii · 2025Article
- Linear IgA bullous dermatosis secondary to drugs: a real-world pharmacovigilance study of the FDA adverse event reporting system.Frontiers in medicine · 2025Article
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- [Blisters in a "cluster of jewels"-like pattern in a child with chronic hepatitis B infection].Dermatologie (Heidelberg, Germany) · 2024Article
- Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.Frontiers in immunology · 2024Review
- Linear IgA bullous dermatosis after COVID-19 vaccination.International journal of dermatology · 2023Article
- Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine.Journal of cutaneous pathology · 2023Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.Journal of autoimmunity · 2022Review
- Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review.Pathology, research and practice · 2022Review
- Linear Immunoglobulin a Bullous Dermatosis in Children.Frontiers in pediatrics · 2022Review
- Linear IgA bullous dermatosis: 32 years of experience.Anais brasileiros de dermatologiaArticle
- Vesiculobullous and Other Cutaneous Manifestations of COVID-19 Vaccines: a Scoping and Narrative Review.Journal of cutaneous medicine and surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A case of linear IgA bullous dermatosis developing 3 days after the second dose of Oxford AstraZeneca COVID-19 vaccine in an adult patient, suggesting a possible causal association. It is worth keeping in mind that COVID-19 vaccination could induce immune-mediated bullous disease in susceptible people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.